Joincare(SH:600380) 市值风云·2025-12-05 10:04Core Viewpoint - The article highlights the imminent peak of flu activity in China, with a significant rise in flu cases and the potential market opportunities for vaccine and antiviral drug manufacturers, particularly focusing on the innovative drug Marpapsavir by Health元 [3][4][5]. Group 1: Flu Activity and Market Impact - The flu positivity rate in China has approached 45%, indicating a shift to an epidemic level, with some provinces experiencing high levels of flu activity [3]. - Experts predict that flu peaks will occur in mid-December for some provinces, while most will see peaks in late December, followed by a decline in early January [4]. - Companies like 华兰疫苗 (Hualan Biological Engineering) and 金迪克 (Gendik) are directly linked to flu vaccine production, while Health元's Marpapsavir is positioned as a leading antiviral treatment [5]. Group 2: Marpapsavir's Advantages - Marpapsavir is noted for its single-dose oral administration and ability to inhibit virus replication within 24 hours, outperforming daily dosage requirements of existing treatments like Oseltamivir [5]. - Clinical trials indicate that Marpapsavir provides faster symptom relief in patients with influenza B and shows lower resistance risks, making it a preferred option for high-risk groups [5]. Group 3: Health元's Innovation Pipeline - Health元 has a robust pipeline with over 10 first-class innovative drugs in respiratory diseases, including treatments for asthma and COPD, with several in advanced clinical stages [8]. - The company has 39 products in development, with 13 at the application stage and 4 in Phase III clinical trials, indicating a strong commitment to innovation [9]. Group 4: R&D Investment - Health元's R&D expenses reached 931 million in the first three quarters of 2025, consistently representing around 10% of its revenue over recent years, showcasing its dedication to innovation [12]. - Historical R&D spending from 2020 to 2024 shows a steady investment trend, with a peak in 2021 at 1.85 billion, reflecting the company's focus on developing innovative therapies [13].